CA-QUANERGY-SYSTEMS
13.7.2021 12:02:09 CEST | Business Wire | Press release
Quanergy Systems, Inc ., a leading provider of OPA-based solid state LiDAR sensors and smart 3D solutions for automotive and IoT, today announced that it has expanded its exclusive agreement with PARIFEX, a leading solution provider in project management for speed enforcement and smart cities, to deploy Quanergy’s M-Series 3D-LiDAR sensors for highway speed monitoring and enforcement. The new project will be deployed with the French Ministry of Interior, with future expansion to global projects.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210713005506/en/
The M8 LiDAR sensor from Quanergy features an extended range up to 200 meters and a superior angular beam resolution of 0.033 degrees, enabling highly accurate and reliable detection of speeding violations even in busy, fast-paced highway environments. The sensor will be integrated exclusively into the VIGIE Double-Side solutions by PARIFEX, an extra-urban speed control system able to track, identify and classify different vehicles simultaneously on different lanes and identify the speeding one through a picture of the front and the rear of the vehicle.
PARIFEX offers the only approved LiDAR-based system for speed measurement and control in France. Building on a multi-year partnership, this project will accelerate the goal of achieving safer highway systems.
“We have been committed to providing innovative and reliable solutions for many years to take part in the improvement of road safety, especially on fast highways,” said Franck Peyré, CEO at PARIFEX, “We chose Quanergy’s LiDAR for its accuracy to strengthen the VIGIE Double-Side solution, long-range detection at high speeds, as well as its high performance in challenging conditions. Our first project with Quanergy, which was deployed in Rouen France, confirmed our decision to continue leveraging Quanergy’s LiDAR technology in the VIGIE Double-Side.”
The fully automated, LiDAR-based VIGIE Double-Side monitors multiple lanes of traffic to detect, classify, and identify vehicles exceeding posted speed limits. This solution simultaneously measures the speed of all vehicles, and it can identify an offending vehicle from hundreds of meters upstream. The solution automatically classifies the category of vehicle (truck, passenger car, motorcycle, etc.) and adapts the speed threshold accordingly.
“From our first deployment in 2017, Quanergy and PARIFEX have worked together to leverage 3D LiDAR technology to make the world a safer place--one highway at a time,” said Enzo Signore, CMO at Quanergy, “This continuous deployment with PARIFEX is an important step towards a future with fewer road accidents.”
For more information, visit www.quanergy.com
About Quanergy Systems, Inc.
Quanergy Systems’ mission is to create powerful, affordable smart LiDAR solutions for automotive and IoT applications to enhance people’s experiences and safety. Quanergy has developed the only true 100% solid state CMOS LiDAR sensor built on optical phased array (OPA) technology to enable the mass production of low-cost, highly reliable 3D LiDAR solutions. Through Quanergy’s smart LiDAR solutions, businesses can now leverage real-time, advanced 3D insights to transform their operations in a variety of industries including industrial automation, physical security, smart cities, smart spaces, and much more. Quanergy solutions are deployed by over 350 customers across the globe. For more information, please visit us at www.quanergy.com .
About PARIFEX
PARIFEX is a leading solution provider in project management, helping its clients in all fields of activity in the conception, management, development, and integration of their great engineering projects in industry and road safety. Through its expertise, the company also designs leading solutions for projects such as smart cities, new mobility, and more. PARIFEX was founded in 1994 and has branches in Europe and Asia, along with clients throughout the world. For more information, visit www.parifex.com/en .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210713005506/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom